

KDventures exercises its share of the portfolio company Modus Therapeutics' warrant program TO2

STOCKHOLM, SWEDEN April 14, 2026. KDventures AB (Nasdaq Stockholm: KDV) today announces that it is exercising its share of the portfolio company Modus Therapeutics' warrant program series 2025/2026 (TO2).

The exercise period in the portfolio company Modus Therapeutics' warrant program TO2 runs between April 13–24 2026, and the subscription price amounts to SEK 0.35 per share. KDventures is exercising all of its warrants, corresponding to approximately SEK 5.1 million.

Upon full exercise of the warrant program, Modus Therapeutics, listed on Nasdaq First North Growth Market, will receive about SEK 10 million before transaction costs.

KDventures' ownership in Modus Therapeutics amounts to 56 percent directly and 2 percent indirectly via KDev Investments.

Contacts

Viktor Drvota, CEO, KDventures AB

Phone: +46 73 982 52 02, e-mail: viktor.drivota@kd-ventures.com

Johan Dighed, General Counsel and Deputy CEO, KDventures AB

Phone: +46 70 207 48 26, e-mail: johan.dighed@kd-ventures.com

About Us

KDventures AB (Nasdaq Stockholm: KDV) is a Nordic investment company specialized in life sciences. The company identifies and invests in innovative pharmaceutical projects and medical technology products originating from leading research institutions in the Nordic region. Through a diversified portfolio across various stages of development, professional due diligence, and active board engagement, KDventures creates value from early research to commercialization. The company offers investors exposure to both listed and private life science projects with significant value growth potential.

For more information, please visit <https://www.kd-ventures.com/en>.